Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Hutchmed (HCM) Share Price

Intraday
Historical

Price	212.00p on 18-04-2025 at 04:45:10
Change	0.00p 0%
Buy	212.00p
Sell	209.00p
Buy / Sell HCM Shares

Last Trade:	Sell 12,500.00 at 212.00p
Day's Volume:	0
Last Close:	212.00p
Open:	0.00p
ISIN:	KYG4672N1198

Day's Range	0.00p - 0.00p
52wk Range:	187.50p - 353.00p
Market Capitalisation:	£1,812m
VWAP:	0.00p
Shares in Issue:	855m

Sector: Medicine and Biotech

Listed In: FTSE AIM 100, FTSE AIM All-Share,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Hutchmed (HCM) Latest Trades
Sell*	12,500	212.00p	Uncrossing Trade	16:35:11 - 17-Apr-25
Buy*	232	212.00p	Automatic Execution	16:20:02 - 17-Apr-25
Sell*	159	209.00p	Automatic Execution	16:04:38 - 17-Apr-25
Buy*	1	210.9297p	Ordinary	15:56:18 - 17-Apr-25
Sell*	42	209.00p	Automatic Execution	15:30:48 - 17-Apr-25
Sell*	466	209.00p	Automatic Execution	15:30:48 - 17-Apr-25
Sell*	217	209.00p	Automatic Execution	15:30:48 - 17-Apr-25
Sell*	417	209.00p	Automatic Execution	15:30:48 - 17-Apr-25
Sell*	1	210.80p	Ordinary	15:22:18 - 17-Apr-25
Buy*	1	213.2162p	Ordinary	15:22:18 - 17-Apr-25

See more Hutchmed trades

Hutchmed (HCM) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
18th Apr 2025 (Fri)	212.00	212.00	212.00	212.00	0
17th Apr 2025 (Thu)	212.00	214.00	209.00	212.00	22,713
16th Apr 2025 (Wed)	211.00	214.00	207.00	207.00	17,049
15th Apr 2025 (Tue)	219.00	220.00	215.00	218.00	26,478
14th Apr 2025 (Mon)	215.00	228.00	215.00	225.00	97,113
11th Apr 2025 (Fri)	199.50	212.00	199.50	208.00	304,294
10th Apr 2025 (Thu)	194.00	213.00	194.00	196.50	33,050
9th Apr 2025 (Wed)	199.50	209.00	187.50	189.00	46,947
8th Apr 2025 (Tue)	204.00	206.00	194.00	194.00	42,678
7th Apr 2025 (Mon)	205.00	207.00	189.00	195.00	95,082
4th Apr 2025 (Fri)	234.00	234.00	211.00	223.50	52,933
3rd Apr 2025 (Thu)	241.00	241.00	230.00	236.00	17,237
2nd Apr 2025 (Wed)	247.00	249.00	243.00	249.00	6,441
1st Apr 2025 (Tue)	250.00	260.00	248.00	256.00	155,774
31st Mar 2025 (Mon)	233.00	233.00	229.00	232.00	45,713
28th Mar 2025 (Fri)	239.00	239.00	232.00	237.00	67,448
27th Mar 2025 (Thu)	228.00	237.00	228.00	235.00	84,885
26th Mar 2025 (Wed)	228.00	228.00	218.00	218.00	20,318
25th Mar 2025 (Tue)	231.00	231.00	225.00	227.00	24,426
24th Mar 2025 (Mon)	231.00	239.00	231.00	233.00	12,764
21st Mar 2025 (Fri)	241.00	242.00	227.00	227.00	157,572
20th Mar 2025 (Thu)	256.00	259.00	250.00	250.00	26,478
19th Mar 2025 (Wed)	238.00	257.00	238.00	245.00	39,148

See more Hutchmed price history

Date	Source	Headline
Hutchmed (HCM) Regulatory News
7th Apr 2025 9:30 am	RNS	2024 Annual Report and Notice of AGM
31st Mar 2025 10:30 am	RNS	Extraordinary General Meeting – Poll Results
21st Mar 2025 10:00 am	RNS-R	NMPA Conditional Approval for TAZVERIK®
20th Mar 2025 9:30 am	RNS	Retirement of Independent Non-executive Directors
20th Mar 2025 7:00 am	RNS-R	HUTCHMED Highlights Savolitinib SAVANNAH Phase II
19th Mar 2025 1:45 pm	RNS-R	Publication of Form 20-F
19th Mar 2025 11:00 am	RNS	2024 Final Results and Business Updates
19th Mar 2025 7:00 am	RNS-R	Phase II/III Study of Fruquintinib and Sintilimab
14th Mar 2025 9:30 am	RNS	Adoption of the 2025 Long Term Incentive Plan
14th Mar 2025 9:30 am	RNS	Vesting of awards under Long Term Incentive Plan

See more Hutchmed regulatory news

Hutchmed (HCM) Share News

IN BRIEF: Hutchmed China's Tazverik conditionally approved in China

21st Mar 2025 12:23

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - The new drug application for Tazverik has been granted conditional approval by the National Medical Products Administration in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with the EZH2 gene mutation who have received at least two prior systemic therapies. Approval was based on positive results from a phase II bridging study in China, and clinical studies conducted by Epizyme Inc, a subsidiary of Paris-based pharmaceutical firm Ipsen SA. Read More

IN BRIEF: Hutchmed highlights positive lung cancer test results

20th Mar 2025 14:31

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More

Hutchmed China celebrates kidney cancer treatment; swings to loss

19th Mar 2025 12:08

(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. Read More

UK earnings, trading statements calendar - next 7 days

12th Mar 2025 14:31

IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China

14th Jan 2025 12:07

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial. Read More

See more Hutchmed news

FTSE 100 Latest

Value8,275.66

Change0.00

Hutchmed (HCM) Share Price

Login to your account